Inhaled Treprostinil Benefit Affirmed in Idiopathic Pulmonary Fibrosis

(MedPage Today) -- Nebulized treprostinil (Tyvaso) reduced lung function decline from idiopathic pulmonary fibrosis (IPF) in the pivotal TETON-1 trial, mirroring positive results from the parallel TETON-2 trial. Declines from baseline to week...
Source
MedPage Today
Opens original article in a new tab



